Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹686.55 Cr |
| Fresh Issue | ₹490.00 Cr |
| Offer for Sale | ₹196.55 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹285.00-300.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543950 |
| NSE Code | YATHARTH |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Intensive Fiscal Services Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 50 shares and in multiples thereof
Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospital chain. Yatharth Hospital operates through its super specialty hospitals. These hospitals are situated in Delhi NCR, i.e., at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. The hospital located in Noida Extension Hospital has 450 beds and is one of the largest hospitals in the area.
Yatharth Hospital and Trauma Care Services provide patients with various Amenities and facilities. All of their hospitals are accredited by the NABH. And the ones located at Greater Noida and Noida Extension are accredited by NABL. The hospitals comply with all necessary international quality standards to ensure safety and recovery of the patients.
The company acquired a 305-bedded multi-specialty hospital in Orchha, Madhya Pradesh to extend its operations and services.
A team of 370 doctors is engaged with the company. They offer healthcare services across numerous specialties and super specialties.
The super specialty or Centres of Excellence (COE) of the hospital includes:
Centre of Medicine, Centre of General Surgery, Centre of Gastroenterology, Centre of Cardiology, Centre of Nephrology & Urology, Centre of Pulmonology, Centre of Neurosciences, Centre of Paediatrics, Centre of Gynaecology, Centre of Orthopaedics and Spine & Rheumatology.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/ prepayment, in full or part, of certain borrowings availed by the Company. | 100.00 |
| 2 | Repayment/ prepayment, in full or part, of certain borrowings availed by our Subsidiaries, namely, AKS Medical & Research Centre Private Limited (“AKS”) and Ramraja Multispeciality Hospital & Trauma Centre Private Limited (“Ramraja”) | 145.00 |
| 3 | Funding capital expenditure expenses of our Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital. | 25.64 |
| 4 | Funding capital expenditure expenses of our Subsidiaries, AKS and Ramraja, for respective hospital operated by them. | 106.97 |
| 5 | Funding inorganic growth initiatives through acquisitions and other strategic initiatives | 65.00 |
| 6 | General corporate purposes. | 127.10 |
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|---|
| Assets | 485.97 | 426.02 | 308.77 | 287.20 | 256.56 |
| Total Income | 523.10 | 402.59 | 229.19 | 146.18 | 102.07 |
| Profit After Tax | 65.77 | 44.16 | 19.59 | -2.05 | 3.98 |
| NET Worth | 182.96 | 116.89 | 72.46 | 54.29 | 55.60 |
| Total Borrowing | 263.78 | 258.19 | 186.11 | 184.57 | 164.57 |
| Amount in ₹ Crore | |||||
| KPI | |
|---|---|
| ROE | 35.95% |
| ROCE | 26.10% |
| Debt / Equity | 1.44% |
| RoNW | 35.95% |
| PAT Margin | 12.64% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 10.09 | |
| P/E (x) | 39.16 | |
| Promoter Holding | 91.34% | 66.32% |
| Market Cap | ₹2575.51 Cr. | |
